Inventor · disambiguated record
Miroslav Rapta
Also filed as: RAPTA MIROSLAV
62 granted patents·4 pending applications·416 citations·filing 2005–2024
99Inventor score
Files withTHERAVANCE BIOPHARMA R&D IP LLC30THERAVANCE INC8DALZIEL SEAN M7RAPTA MIROSLAV5CHAO ROBERT S3
Top patents by PatentIndex Score
66 records- 0197US10946006B2Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Mar 16, 2021·4 cites·25 claims
- 0297US8247433B2Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundsSTANGELAND ERIC L·Filed 2009·Granted Aug 21, 2012·23 cites·9 claims
- 0397US7524965B2Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activityTHERAVANCE INC·Filed 2007·Granted Apr 28, 2009·44 cites·10 claims
- 0496US9073859B2Crystalline form of a 4-[2-(2-fluorophenoxymethyl) phenyl]piperidine compoundPATTERSON LORI JEAN·Filed 2013·Granted Jul 7, 2015·18 cites·7 claims
- 0596US8304433B2Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundPATTERSON LORI JEAN·Filed 2009·Granted Nov 6, 2012·23 cites·9 claims
- 0696US7320990B2Crystalline form of a biphenyl compoundTHERAVANCE INC·Filed 2005·Granted Jan 22, 2008·28 cites·21 claims
- 0795US10226454B2Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Mar 12, 2019·8 cites·18 claims
- 0895US8592596B2Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundTHERAVANCE INC·Filed 2012·Granted Nov 26, 2013·15 cites·5 claims
- 0995US7521558B2Crystalline form of a biphenyl compoundTHERAVANCE INC·Filed 2005·Granted Apr 21, 2009·27 cites·12 claims
- 1094US10576073B2Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Mar 3, 2020·6 cites·11 claims
- 1194US7943772B2Crystalline forms of an 8-azabicyclo(3.2.1)octane compoundTHERAVANCE INC·Filed 2008·Granted May 17, 2011·24 cites·13 claims
- 1294US7687521B2Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activityTHERAVANCE INC·Filed 2009·Granted Mar 30, 2010·23 cites·11 claims
- 1393US11230536B2Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Jan 25, 2022·2 cites·20 claims
- 1493US8536335B2Crystalline forms of an 8-azabicyclo[3.2.1]octane compoundDALZIEL SEAN M·Filed 2012·Granted Sep 17, 2013·14 cites·6 claims
- 1592US8247555B2Crystalline forms of an 8-azabicyclo[3.2.1]octane compoundDALZIEL SEAN M·Filed 2011·Granted Aug 21, 2012·15 cites·20 claims
- 1692US8101766B2Crystalline form of a biphenyl compoundCHAO ROBERT S·Filed 2009·Granted Jan 24, 2012·18 cites·9 claims
- 1791US11596624B2Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Mar 7, 2023·1 cites·7 claims
- 1891US9533962B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jan 3, 2017·6 cites·28 claims
- 1991US8134006B2Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activityCOLSON PIERRE-JEAN·Filed 2010·Granted Mar 13, 2012·15 cites·8 claims
- 2090US7880010B2Crystalline forms of a dimethylphenyl compoundTHERAVANCE INC·Filed 2007·Granted Feb 1, 2011·17 cites·13 claims
- 2189US12239638B2Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2023·Granted Mar 4, 2025·0 cites·14 claims
- 2289US11718591B2Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Aug 8, 2023·1 cites·20 claims
- 2389US9872855B2(2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jan 23, 2018·5 cites·9 claims
- 2488US11033533B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Jun 15, 2021·1 cites·20 claims
- 2588US9290491B2Crystalline forms of an 8-azabicyclo[3.2.1]octane compoundDALZIEL SEAN M·Filed 2014·Granted Mar 22, 2016·6 cites·2 claims
- 2687US10538513B2Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Jan 21, 2020·4 cites·16 claims
- 2787US10472335B2Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-bipheny]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Nov 12, 2019·4 cites·15 claims
- 2887US10172834B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jan 8, 2019·3 cites·3 claims
- 2987US10100021B2Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Oct 16, 2018·4 cites·24 claims
- 3087US9949963B2Crystalline forms of an 8-azabicyclo[3.2.1]octane compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Apr 24, 2018·4 cites·7 claims
- 3187US8962864B2Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compoundsRAPTA MIROSLAV·Filed 2013·Granted Feb 24, 2015·3 cites·12 claims
- 3287US8802857B2Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundsSTANGELAND ERIC L·Filed 2012·Granted Aug 12, 2014·4 cites·4 claims
- 3387US8163794B2Crystalline form of a 3-phenoxymethylpyrrolidine compoundSAITO DAISUKE ROLAND·Filed 2011·Granted Apr 24, 2012·7 cites·15 claims
- 3486US10752599B2Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Aug 25, 2020·3 cites·20 claims
- 3585US12351561B2Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2024·Granted Jul 8, 2025·0 cites·63 claims
- 3685US10392368B2Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Aug 27, 2019·5 cites·46 claims
- 3784US10548879B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Feb 4, 2020·2 cites·20 claims
- 3884US10426766B2Crystalline forms of an 8-azabicyclo[3.2.1]octane compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Oct 1, 2019·2 cites·6 claims
- 3984US9187423B2Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compoundsSTANGELAND ERIC L·Filed 2014·Granted Nov 17, 2015·2 cites·2 claims
- 4084US8816091B2Crystalline forms of an 8-azabicyclo[3.2.1]octane compoundDALZIEL SEAN·Filed 2013·Granted Aug 26, 2014·7 cites·17 claims
- 4184US8106232B23-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonistsTRAPP SEAN G·Filed 2008·Granted Jan 31, 2012·5 cites·17 claims
- 4283US10968205B2Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Apr 6, 2021·1 cites·26 claims
- 4382US8101794B2Crystalline forms of a 3-carboxypropyl-aminotetralin compoundDALZIEL SEAN M·Filed 2009·Granted Jan 24, 2012·3 cites·6 claims
- 4479US11718616B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Granted Aug 8, 2023·0 cites·7 claims
- 4579US11642332B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted May 9, 2023·0 cites·20 claims
- 4677US8324236B2Crystalline forms of a 3-carboxypropyl-aminotetralin compoundDALZIEL SEAN M·Filed 2011·Granted Dec 4, 2012·2 cites·5 claims
- 4774US9676742B2Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compoundRAPTA MIROSLAV·Filed 2015·Granted Jun 13, 2017·1 cites·8 claims
- 4874US9096577B2Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compoundRAPTA MIROSLAV·Filed 2015·Granted Aug 4, 2015·1 cites·5 claims
- 4974US8933111B2Crystalline form of (2S,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)-amino]-pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl esterRAPTA MIROSLAV·Filed 2013·Granted Jan 13, 2015·2 cites·14 claims
- 5073US8486958B2Crystalline forms of a 3-carboxypropyl-aminotetralin compoundDALZIEL SEAN M·Filed 2012·Granted Jul 16, 2013·1 cites·14 claims
Showing the top 50 of 66 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →